OBJECTIVE： To explore the model and content of pharmaceutical care for a mediastinal infection patient with severe sepsis. METHODS： Clinical pharmacists participated in drug therapy for a mediastinal infection patient with severe sepsis and formulated therapy plan in respects of drug selection， dose， therapeutic efficacy， treatment course and ADR， etc. They also provided pharmaceutical care for the patient. The initial anti-infective plan was as follows： meropenem 1.0 g，ivgtt，q8 h+vancomycin 0.75 g，ivgtt， q12 h. Due to poor infection control effect， clinical pharmacists suggested changing therapy plan：  Piperacillin sodium and tazobactam sodium for injection 4.5 g， ivgtt， q8 h+Metronidazole and sodiu chloride injection 0.5 g， ivgtt， q8 h. And then anti-infective plan was replaced considering about anaerobic infection， as levofloxacin 0.5 g，ivgtt，qd. Clinical pharmacists provide suggestions on anti-systemic inflammatory response

dehydration relief， enteral nutrition and other aspects. RESULTS： The physicians adopted the suggestion of clinical pharmacists. After 14 days of treatment in ICU， the patient took off ventilator； the patient’s body temperature returned to normal， and blood routine decreased significantly compared to before treatment； the vital signs were sable， then the patient was transefered out of the ICU to consolidate the treatment. CONCLUSIONS： Clinical pharmacists participate in individualized pharmaceutical care， and provide reliable evidence for rational drug use to guarantee the safety of drug use.